Pharmacy Times: CGM use cuts calories

Continuous glucose monitors are turning into something bigger than a diabetes gadget. They still track glucose every few minutes, but the newer pitch is behavior change — show people what food, exercise, stress, and sleep are doing in near real time, then use that feedback to nudge better choices. That is the core idea in a March 12, 2024 Pharmacy Times guide aimed at pharmacists, and it lands differently now because the consumer market caught up fast. OTC devices arrived in 2024, and newer reviews in 2025 and 2026 give the “CGM as feedback tool” argument more support. ### What’s the actual claim here? The claim is not that a sensor magically makes people healthier. It’s that seeing glucose rise after a meal or settle after a walk can make advice feel concrete instead of abstract. The Pharmacy Times piece frames pharmacists as the people who can turn those traces into action — helping with device choice, training, interpretation, and medication or lifestyle adjustments. (pharmacytimes.com) ### Why would that change eating? Because biofeedback is sticky. “Eat better” is vague. “That breakfast spiked you for two hours” is not. A 2026 systematic review and meta-analysis of 28 studies in diabetes found CGM use was linked to lower daily calorie intake by about 70.8 kcal and lower carbohydrate intake by about 19.9 g per day versus controls. That is not huge on any single day, but it is exactly the kind of small, repeated change behavior tools are supposed to create. (pharmacytimes.com) ### Does it also change exercise? Looks like yes, at least modestly. That same 2026 review found CGM users added about 16.2 minutes of physical activity per day. An earlier article reviewing the question pointed to one 3-month comparison where people using CGM averaged 346 minutes of weekly exercise versus 235 minutes with standard self-monitoring. The pattern is pretty intuitive — people see post-meal glucose bumps, take a walk, and watch the curve flatten. (pmc.ncbi.nlm.nih.gov) ### Is this strongest in diabetes or outside it? Still strongest in diabetes — especially type 2 diabetes. A 2025 meta-analysis focused on CGM-guided lifestyle choices in type 2 diabetes found better HbA1c, more time in range, lower fasting glucose, and about 2.06 kg lower body weight. That matters because it suggests the feedback is not just changing habits on paper; it can move clinical outcomes too. (pmc.ncbi.nlm.nih.gov) ### What about people not using insulin? That used to be a gray zone, and it still partly is. The evidence base is thinner there, but practice is moving. A 2025 Clinical Diabetes case series described CGM-guided nutrition in people with type 2 diabetes not using insulin, and the ADA added a 2025 recommendation to consider CGM in adults with type 2 diabetes using any glucose-lowering medication. So the center of gravity is shifting away from “CGM is only for insulin.” (pmc.ncbi.nlm.nih.gov) ### Why is this suddenly a consumer story? Because regulators opened the door. The FDA cleared Dexcom Stelo on March 5, 2024 as the first OTC CGM for adults 18 and older who do not use insulin, including people without diabetes who want to understand how diet and exercise affect blood sugar. Abbott’s Lingo followed in June 2024. Once that happened, CGMs stopped being only a clinic tool and started becoming a wellness product too. (diabetesjournals.org) ### So what’s the catch? The catch is that more data is not the same as more health. In adults without diabetes, there still is no large randomized trial showing CGMs reliably produce meaningful long-term health gains. Some people may learn useful patterns. Others may just end up staring at harmless glucose wiggles. The signal is promising, but the evidence is much firmer for diabetes care than for general optimization. (fda.gov) ### Bottom line? CGMs are becoming a feedback layer for behavior, not just a glucose readout. That is the real shift. The best-supported version is still in type 2 diabetes, where newer evidence shows small but measurable drops in calories, carbs, weight, and better activity and glucose control. But OTC access means the experiment is now happening in the open — with pharmacists, coaches, and consumers all trying to turn a stream of numbers into better habits. (clinicalcorrelations.org) (pmc.ncbi.nlm.nih.gov)